Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society
- PMID: 2212128
- DOI: 10.1016/0190-9622(90)70214-3
Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society
Abstract
Years of potential life lost (YPLL) is an indicator of premature mortality that complements traditional incidence and mortality rates and that facilitates comparisons among different cancers. We calculated YPLL from cutaneous melanoma and 11 other cancers routinely recorded and tracked by Surveillance, Epidemiology and End Results (SEER). YPLL from cutaneous melanoma ranked eighth for persons younger than 65 years of age and fourth for those 20 to 49 years of age. An average of 17.1 YPLL per death were due to melanoma, one of the highest rates for adult-onset cancers. The results of our study, the first to apply YPLL to cutaneous melanoma, emphasize the disproportionate impact of this cancer on young and middle-aged adults and reemphasize the importance of this cancer as a public health priority.
Similar articles
-
The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006.J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S133-43. doi: 10.1016/j.jaad.2011.04.036. J Am Acad Dermatol. 2011. PMID: 22018062
-
Potential gains in life expectancy or years of potential life lost: impact of competing risks of death.Int J Epidemiol. 1999 Oct;28(5):894-8. doi: 10.1093/ije/28.5.894. Int J Epidemiol. 1999. PMID: 10597988
-
Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009.Cancer Med. 2015 Apr;4(4):608-19. doi: 10.1002/cam4.410. Epub 2015 Jan 27. Cancer Med. 2015. PMID: 25627000 Free PMC article.
-
Years of potential life lost and productivity losses from male urogenital cancer deaths--United States, 2004.Urology. 2010 Sep;76(3):528-35. doi: 10.1016/j.urology.2010.04.030. Epub 2010 Jun 22. Urology. 2010. PMID: 20573389 Review.
-
Epidemiology of cutaneous melanoma. An update.Dermatol Clin. 1991 Oct;9(4):617-29. Dermatol Clin. 1991. PMID: 1934636 Review.
Cited by
-
1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma.Biochem Pharmacol. 2012 Dec 1;84(11):1419-27. doi: 10.1016/j.bcp.2012.08.020. Epub 2012 Aug 28. Biochem Pharmacol. 2012. PMID: 22959823 Free PMC article.
-
Uncertainty quantification of years of potential life lost-based estimates from mortality data summarized as death counts within age intervals.Ann Epidemiol. 2021 Mar;55:1-3. doi: 10.1016/j.annepidem.2020.11.002. Epub 2020 Nov 19. Ann Epidemiol. 2021. PMID: 33220436 Free PMC article. No abstract available.
-
Statins and fibrates for preventing melanoma.Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD003697. doi: 10.1002/14651858.CD003697.pub2. Cochrane Database Syst Rev. 2005. PMID: 16235336 Free PMC article.
-
WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.Oncol Lett. 2012 Apr 1;3(4):751-755. doi: 10.3892/ol.2012.578. Epub 2012 Jan 19. Oncol Lett. 2012. PMID: 22740987 Free PMC article.
-
Improving the early detection of malignant melanoma.Ann R Coll Surg Engl. 1996 May;78(3 ( Pt 1)):176-9. Ann R Coll Surg Engl. 1996. PMID: 8779497 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical